Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Altimmune, Inc. (NASDAQ:ALT) have received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $20.00.

A number of equities analysts have weighed in on ALT shares. UBS Group started coverage on Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a research report on Thursday, November 14th.

Altimmune Trading Down 0.1 %

ALT opened at $7.25 on Tuesday. The stock has a market capitalization of $515.66 million, a P/E ratio of -4.68 and a beta of 0.22. Altimmune has a 12 month low of $5.28 and a 12 month high of $14.84. The firm’s fifty day simple moving average is $8.07 and its 200 day simple moving average is $7.19.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.03. The company had revenue of $0.01 million for the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same quarter last year, the firm earned ($0.39) earnings per share. On average, equities research analysts predict that Altimmune will post -1.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp increased its holdings in shares of Altimmune by 28.6% during the second quarter. Bank of New York Mellon Corp now owns 243,808 shares of the company’s stock worth $1,621,000 after purchasing an additional 54,154 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Altimmune by 190.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,688 shares of the company’s stock worth $98,000 after acquiring an additional 9,635 shares in the last quarter. Principal Financial Group Inc. bought a new position in Altimmune in the second quarter valued at approximately $70,000. Commonwealth Equity Services LLC raised its position in Altimmune by 9.0% during the second quarter. Commonwealth Equity Services LLC now owns 87,110 shares of the company’s stock valued at $579,000 after purchasing an additional 7,165 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in Altimmune by 25.8% during the second quarter. Rhumbline Advisers now owns 107,446 shares of the company’s stock worth $715,000 after purchasing an additional 22,034 shares during the last quarter. 78.05% of the stock is owned by institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.